Skip to content

Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT

Clinical Study of Moxibustion in the Treatment of Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06241274
Enrollment
60
Registered
2024-02-05
Start date
2024-08-15
Completion date
2025-12-31
Last updated
2024-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic Stem Cell Transplantation, Hemorrhagic Cystitis, Moxibustion, Treatment

Brief summary

This study was a prospective, multicenter, single-arm clinical study planned to enroll 60 patients who developed hemorrhagic cystitis after sexually allogeneic hematopoietic stem cell transplantation Patients with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation were given symptomatic supportive treatment combined with moxibustion covering Shenque, Zhongguo, Guanyuan, and Qihai for 30 minutes every day for 14 days and urine routine was collected every day for 14 days to assess the severity of hemorrhagic cystitis and pain scores to evaluate the effectiveness of moxibustion in treating hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.

Interventions

OTHERMoxibustion

Subjects received moxibustion covering Shenque, Zhonggong, Guanyuan, and Qihai for 30 minutes every day for 14 days.

OTHERSymptomatic supportive treatment

Symptomatic supportive treatment.

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

1. patients were fully aware of the study, participated voluntarily, and signed the informed consent form; 2. Age: 18-55 years old; 3. patients with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation;

Exclusion criteria

1. refusal to participate in this clinical study; 2. broken or sensitized skin corresponding to the moxibustion site; 3. allogeneic hematopoietic stem cell transplantationpatients pretreated with the Reduced-intensity conditioning.

Design outcomes

Primary

MeasureTime frameDescription
Core Lower Urinary Tract Symptom Score14 daysThe Core Lower Urinary Tract Symptom Score consists of 10 questions. Frequent daytime urination---0 points:\<7 times;1 point:8\ 9 times;2 points:10\ 14 times;3 points:\> 14 times. Nocturia---0 points:0 times/night;1 point:1 time/night;2 points: 2\ 3 times/night;3 points:\> 3 times/night. The other 8 problems were urgency, dysuria, hesitancy, thin urine line, urge incontinence, stress incontinence, bladder pain, and urethral pain, which were rated as 0, 1, 2, and 3 according to their frequency (never, rarely, sometimes, and often).

Countries

China

Contacts

Primary ContactYi Zhang
zy188603@163.com+86 15639790587

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026